Status:
COMPLETED
Role of Osteocytes in Myeloma Bone Disease
Lead Sponsor:
Attaya Suvannasankha
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Progress in the treatment of myeloma and myeloma bone disease has substantially increased overall survival, but relapse is inevitable and better treatment is needed. The bone microenvironment is treme...
Eligibility Criteria
Inclusion
- Age \> 18 years but ≤ 95 years at the time of consent
- Subjects must be English-speaking
- Must voluntarily sign the most current informed consent and HIPAA documents prior to study participation.
- Have no prior history of malignancy in the past 5 years with the exception of basal cell and squamous cell carcinoma of the skin. Other cancers with low potential for metastasis, such as in situ cancers can also be enrolled as healthy volunteers.
- Have no known liver or kidney disorders
Exclusion
- Pregnant females will be excluded from the study.
- Subjects allergic to xylocaine will be excluded.
- Subjects with an acute illness (Ex. upper respiratory infection, viral illness) in the past seven days will be excluded.
- History of bleeding disorders.
- Subjects deemed incompetent by treating physician
- Institutionalized, mentally disabled subjects
- Subjects who are prisoners
Key Trial Info
Start Date :
October 7 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 5 2022
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT02212262
Start Date
October 7 2014
End Date
February 5 2022
Last Update
September 8 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States, 46202
2
VA Roudebush Medical Center
Indianapolis, Indiana, United States, 46202